2021 Marketplace Top Pick Competition - Avita Medical
Summary
- Ramp Up in Burn Revenues as Society Emerges from the Pandemic.
- Hoping for Japan approval in 2021 on Multiple Indications.
- JP Morgan Conference Call Provides Great Update.
Dear Readers,
I have written a few detailed articles on Avita Medical (RCEL) that readers can find here:
Avita Medical: A Better Mousetrap With FDA Approval To Treat Patient Burns
The Stem Cell Triple Play: 3 Companies With Great Value Drivers
The Stem Cell Triple Play Revisited
Avita Medical Enters 2020 With Great Momentum
Furthermore, this presentation at the 2021 JP Morgan Healthcare conference is the best way for investors to get the latest update on the company and why I have chosen for for the contest.
Analyst's Disclosure: I am/we are long RCEL.
These are the personal views of Wall Street Titan Research and should not be relied upon for your investment decisions. All investors should always do their own due diligence.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.